Trial Profile
Phase 1, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Critical Limb Ischemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2019
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Adverse reactions
- Sponsors Helixmith; ViroMed; VM BioPharma
- 17 Sep 2014 New trial record